Kiora Pharmaceuticals (KPRX) Intangibles (2017 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Intangibles came in at $2.1 million in Q1 2026, down 69.15% YoY from $6.7 million in Q1 2025, and little changed on a QoQ basis from $2.1 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Intangibles (2017 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 10 years of Intangibles data on file, last reported at $2.1 million in Q1 2026.
- Quarterly Intangibles fell 69.15% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 69.15% YoY) and the FY2025 annual result came in at $2.1 million, down 69.15% from the prior year.
- Intangibles held at $2.1 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $10.8 million in Q1 2022 to a low of $2.1 million in Q4 2025.
- A 5-year average of $8.1 million and a median of $8.8 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2022 — Intangibles gained 10.69% — and 2025, when it plunged 69.15%.
- Tracing KPRX's Intangibles over 5 years: stood at $10.7 million in 2022, then dropped by 17.96% to $8.8 million in 2023, then declined by 24.13% to $6.7 million in 2024, then sank by 69.15% to $2.1 million in 2025, then changed by 0.0% to $2.1 million in 2026.
- The last three Intangibles figures came in at $2.1 million (Q1 2026), $2.1 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 93.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | 2.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.06 Mn |
| Mar 31, 2026 | 2.06 Mn |
| Dec 31, 2025 | 2.06 Mn |
| Sep 30, 2025 | 6.69 Mn |
| Jun 30, 2025 | 6.69 Mn |
| Mar 31, 2025 | 6.69 Mn |
| Dec 31, 2024 | 6.69 Mn |
| Sep 30, 2024 | 6.69 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Mar 31, 2024 | 8.81 Mn |
| Dec 31, 2023 | 8.81 Mn |
| Sep 30, 2023 | 8.82 Mn |
| Jun 30, 2023 | 10.73 Mn |
| Mar 31, 2023 | 10.74 Mn |
| Dec 31, 2022 | 10.74 Mn |
| Sep 30, 2022 | 10.75 Mn |
| Jun 30, 2022 | 10.76 Mn |
| Mar 31, 2022 | 10.76 Mn |
| Dec 31, 2021 | 10.77 Mn |
| Sep 30, 2021 | 9.71 Mn |